Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
570 Leser
Artikel bewerten:
(2)

Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes

Ghent, BELGIUM, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Press release -inside information

Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes

Company to receive $5.98million in total from the Bill & Melinda Gates Foundation to leverage its AGROBODY technology platform

Ghent, BELGIUM,and Research Triangle Park (NC), UNITED STATES- 20October2021, 07:00 CEST -Biotalys, an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions, today announced it has been awarded a multi-year grant from the Bill & Melinda Gates Foundation to discover novel antifungal biocontrols for deployment to smallholder farmers. The project, identified as "Agrobodies for Crop Protection", focuses on leveraging Biotalys' AGROBODY Foundry technology platform to discover novel protein-based biofungicides with the ability to control Cercosporacanescens, the causative agent of leaf spot disease, an important devastating disease of cowpea and other legumes.

Cowpeas - often referred to as "black-eyed peas" 1 after one of its subspecies - are a subsistence crop, often intercropped with sorghum, maize and pearl millet, providing millions of mainly African farmers, many of whom are women, an affordable source of proteins. According to estimates, cowpeas are cultivated on 14.5 million hectares of land, have a worldwide production of 6.2 million tonnes and are consumed by over 200 million people on a daily basis.2 While the broad range of cowpea varieties has enabled to access more resistant varieties in certain growing regions, the impact of the leaf spot disease (Cercosporacanescens) can still decimate up to 40% of the production for smallholder growers.

During the course of the four-year project, Biotalys will receive a $5.98 million (€5.14 million) grant in non-refundable instalments to achieve, by the end of 2025, proof-of-concept of effective on planta protection of the cowpea crop from leaf spot by an AGROBODY bioactive with potential cross-efficacy against other Cercospora diseases (such as C. beticola) for broader application across different crops.

Patrice Sellès, CEO of Biotalys, stated: "We are delighted to receive this support from the Gates Foundation to apply our knowledge and technology to develop new biological solutions for the protection of cowpeas and other legumes, important subsistence crops for millions of smallholder farmers worldwide. Providing these growers with innovative and affordable tools to protect the yield and quality of their crops without compromising the health of their soils and the safety of their families creates an economical and societal benefit that cannot be achieved with existing chemical pesticides."

"This is an incredible opportunity for the Biotalys team to leverage the antifungal know-how that we have built with our AGROBODY Foundry platform while developing our current product pipeline," saidInge Van Daele, Regulatory Head at Biotalys. "The scope of this new project goes beyond innovation and technology development. This work is about sustainability and making a difference to the lives and health of millions of smallholder farmers and we are proud to have been selected by the Gates Foundation to make an impactful contribution."

The project is aligned with Biotalys' strategy to become an agricultural technology leader by developing unique proprietary protein-based food protection solutions and addresses various Sustainable Development Goals set by the United Nations, such as Zero Hunger (SDG 2), Responsible Consumption and Production (SDG 12), and Life on Land (SDG 15).

About Biotalys

Biotalys is an Agricultural Technology.

For further information, please contact:

Toon Musschoot, Head of Investor Relations & Communications
T: +32

ImportantNotice

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.


1https://www.britannica.com/plant/cowpea

2 Kebede & Bekeko,).

Attachment

  • BMGF Grant 20211020- NL (https://ml.globenewswire.com/Resource/Download/970191a4-318d-4d06-acfb-9efa4a77a51a)

© 2021 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.